9939 주식 개요 임상 단계의 생명공학 회사인 킨토르 제약은 중화인민공화국의 미충족 의료 수요가 있는 피부과 및 종양 적응증에 대한 치료제를 연구, 개발 및 상용화하는 데 주력하고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Kintor Pharmaceutical Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Kintor Pharmaceutical 과거 주가 현재 주가 HK$0.97 52주 최고치 HK$1.98 52주 최저치 HK$0.79 베타 -0.097 1개월 변경 -8.49% 3개월 변경 사항 -11.01% 1년 변경 사항 -40.49% 3년 변화 -92.11% 5년 변화 n/a IPO 이후 변화 -95.49%
최근 뉴스 및 업데이트
Founder recently bought HK$259k worth of stock Dec 14
New major risk - Revenue and earnings growth Nov 06
Founder recently bought HK$107k worth of stock Oct 30
Kintor Pharmaceutical Limited Receives Review Approval of Incorporation for KT-939 Oct 29
Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Pivotal Clinical Trial of Kx-826 Tincture 1.0% for the Treatment of Men Adult Androgenetic Alopecia in China Oct 16
Founder recently bought HK$248k worth of stock Oct 15 더 많은 업데이트 보기
Founder recently bought HK$259k worth of stock Dec 14
New major risk - Revenue and earnings growth Nov 06
Founder recently bought HK$107k worth of stock Oct 30
Kintor Pharmaceutical Limited Receives Review Approval of Incorporation for KT-939 Oct 29
Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Pivotal Clinical Trial of Kx-826 Tincture 1.0% for the Treatment of Men Adult Androgenetic Alopecia in China Oct 16
Founder recently bought HK$248k worth of stock Oct 15
Is Kintor Pharmaceutical (HKG:9939) Using Debt In A Risky Way? Oct 07
Founder recently bought HK$249k worth of stock Sep 21
Founder recently bought HK$424k worth of stock Sep 10
Kintor Pharmaceutical Limited to Report First Half, 2024 Results on Aug 26, 2024 Aug 09
Founder recently bought HK$294k worth of stock Jul 27
Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of GT20029 Gel for Treatment of Ance in China Jun 18
Kintor Pharmaceutical Limited Announces That the Clinical Trial of Its In-House Developed and Potential First-In-Class Kx-826 Tincture 1.0% for the Treatment of Male Adult Androgenetic Alopecia ("Aga") in China (The "Clinical Trial") Was Cleared by the National Medical Products Administration (The "Nmpa") Recently May 25
Kintor Pharmaceutical Limited, Annual General Meeting, Jun 20, 2024 May 22
Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint Apr 23
Kintor Pharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 16
New major risk - Share price stability Feb 02
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA Feb 01
Founder recently bought HK$774k worth of stock Dec 22
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia Nov 29
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia Nov 28
New minor risk - Share price stability Nov 20
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet? Nov 16
New major risk - Financial position Oct 31
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China Oct 12
Insider recently sold HK$2.6m worth of stock Sep 28
Insider recently sold HK$42m worth of stock Sep 06
New major risk - Revenue and earnings growth Aug 30
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China Aug 23
Kintor Pharmaceutical Limited to Report First Half, 2023 Results on Aug 28, 2023 Aug 16
Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826 Jul 22
Kintor Pharmaceutical Limited, Annual General Meeting, Jun 15, 2023 May 13
Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US May 12
Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China May 09
Insider recently sold HK$12m worth of stock Apr 19
Forecast to breakeven in 2023 Mar 31
Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound Feb 11
Kintor Pharmaceutical Limited has completed a Follow-on Equity Offering in the amount of HKD 517.6 million. Dec 17
Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met Dec 02
Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China Nov 25
Less than half of directors are independent Nov 16
Kintor Pharmaceutical Limited Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of Gt20029 in the U.S Oct 28
Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China Oct 17
Kintor Pharmaceutical Limited Announces Publication of Phase Ib Data from Pruxelutamide for Ar+ Mbc in Ejc Sep 29
Consensus revenue estimates fall by 98% Sep 01
Kintor Pharmaceutical Limited to Report First Half, 2022 Results on Aug 29, 2022 Aug 18
Kintor Pharmaceutical Limited Completes Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China Aug 10
Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the Us Aug 04
Key Executive recently sold HK$5.7m worth of stock Jun 13
Kintor Pharmaceutical Limited, Annual General Meeting, Jun 30, 2022 May 31
Insider recently sold HK$60m worth of stock May 23
Kintor Pharmaceutical Limited Announces Board Changes May 08
Kintor Pharmaceutical Limited Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma May 05
Forecast breakeven date pushed back to 2023 May 01
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet? Apr 28
Less than half of directors are independent Apr 27
Kintor Pharmaceutical Limited Announces Top-Line Results of the Phase III MRCT of Proxalutamide in Outpatients with Mild to Moderate Covid-19 Apr 06
Forecast breakeven date pushed back to 2023 Mar 29
Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Aga in Female Patients Mar 07
Kintor Pharma Limited Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US Mar 03
Kintor Pharmaceutical Limited Announces Executive Changes Feb 19
Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients Feb 12 Kintor Pharmaceutical Limited Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne
Kintor Pharma Announces Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826 Jan 25
Kintor Pharmaceutical Limited Announces First Patient Dosing of Phase III Clinical Trial of KX-826 (Pyrilutamide) for Treating Androgenic Alopecia Patients in China Jan 04
Kintor Pharmaceutical Limited Provides Update Interim Analysis for Phase III Study of Proxalutamide for Patients with Mild to Moderate Covid-19 Symptoms Dec 28
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet? Dec 06
Deputy GM & Joint Company Secretary Jie Chen has left the company Dec 01
Non-Executive Director Wei Zhang has left the company Dec 01 Kintor Pharmaceutical Limited Receives IND Clearance by NMPA for KX-826
Kintor Pharmaceutical Limited Announces the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized Covid-19 Patients Sep 27
Non-Executive Director recently bought HK$4.3m worth of stock Sep 16
Kintor Pharmaceutical Limited Announces Primary Endpoint of Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia Sep 09
Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly? Sep 01
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay Jul 16
Kintor Pharmaceutical Limited Announces Investigational New Drug (IND) Clearance by the US FDA for GT20029 for Androgenetic Alopecia and Acne Vulgaris Jul 15
Kintor Pharmaceutical Announces FDA Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US Jul 14
Consensus forecasts updated Jun 24
Kintor Pharmaceutical Limited Receives Approval from Razilian Health Regulatory Agency in the Phase III Clinical Trial of Proxalutamide for Treatment of Male Patients with Mild to Moderate COVID-19 Illness Jun 16
FDA Approves the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalised COVID-19 Patients May 19
Non-Executive Director has left the company May 08
Kintor Pharmaceuticals Announces Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S Apr 26
Kintor Pharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 26, 2021 Mar 13 Kintor Pharmaceutical Limited Announces to Release the Results of the Clinical Trial of Proxalutamide for the Treatment of Hospitalised COVID-19 Patients
Kintor Pharmaceutical Limited Receives Approval from US Food and Drug Administration for Proxalutamide's Phase III COVID-19 Clinical Trial Mar 07
Kintor Pharmaceutical Limited Announces Completion of Patients' Recruitment for Proxalutamide's Covid-19 Hospitalised Study Feb 23
US FDA Approves Kintor Pharmaceutical Limited's Investigational New Drug Application of GT90001's Phase II Clinical Trial for Advanced HCC Feb 19
Kintor Pharmaceutical Limited (HKG:9939) Insiders Increased Their Holdings Feb 17
New 90-day high: HK$16.10 Feb 12
Kintor Pharmaceutical Limited Announces Investigational New Drug Application of GT20029 for Androgenetic Alopecia and Acne Vulgaris Indications Feb 02
Kintor Pharmaceutical Limited Announces Approval of Clinical Trial of Proxalutamide's Treatment of Hospitalized COVID-19 Patients Jan 29
New 90-day high: HK$13.40 Jan 25 Kintor Pharmaceutical Limited Provides Final Results for Male Patients and Interim Results for Female Patients from the Clinical Trial of Proxalutamide for the Treatment of COVID-19
Kintor Pharmaceutical Limited Announces Completion of Patients Enrolment for Pyrilutamide (KX-826)'s Phase II Clinical Trial for Indication of Androgenetic Alopecia in the PRC Jan 01
Kintor Pharmaceutical Limited Announces Board and Committee Changes Dec 30
What Kind Of Investors Own Most Of Kintor Pharmaceutical Limited (HKG:9939)? Dec 23 주주 수익률 9939 HK Biotechs HK 마켓 7D 0% -0.9% 2.1% 1Y -40.5% -13.9% 17.6%
전체 주주 수익률 보기
수익률 대 산업: 9939 지난 1년 동안 -13.9 %를 반환한 Hong Kong Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 9939 지난 1년 동안 17.6 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 9939's price volatile compared to industry and market? 9939 volatility 9939 Average Weekly Movement 12.0% Biotechs Industry Average Movement 11.5% Market Average Movement 8.6% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 3.9%
안정적인 주가: 9939 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: 9939 의 주간 변동성 ( 12% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 임상 단계의 생명공학 회사인 킨토르 제약은 중화인민공화국의 미충족 의료 수요가 있는 피부과 및 종양 적응증에 대한 치료제를 연구, 개발 및 상업화하는 데 주력하고 있습니다. 이 회사의 제품 후보로는 안드로겐성 탈모증과 심상성 여드름 치료를 위한 국소 치료제인 KX-826, 전이성 거세 저항성 전립선암, COVID-19, AR+ 전이성 유방암 치료를 위한 2세대 안드로겐 수용체(AR)인 프록셀루타마이드(GT0918)와 AR-PROTAC 화합물(GT20029) 등이 있습니다. 전이성 거세저항성 전립선암, 코로나19, AR+ 전이성 유방암 치료를 위한 2세대 안드로겐 수용체(AR) 저해제인 프록셀루타마이드(GT0918), 특발성 폐섬유증 및 혈액암 치료를 위한 헤지혹 신호전달 경로 저해제인 GT1708F(Hedgehog/SMO Inhibitor)를 개발 중이며, 전이성 거세저항성 폐암 치료제로는 전립선비대증과 전이성 전립선암을 위한 전립선비대증치료제(GT0486), 전립선비대증치료제 (전립선암치료제) 등을 개발하고 있습니다; 유방암, 전립선암, 간세포암(HCC) 등 전이성 고형 종양 치료를 위한 2세대 mTOR 억제제이자 PI3K/mTOR 신호 전달 경로 억제제인 GT0486; 그리고 전 세계적으로 새로운 생물학적 표적 액틴 수용체 유사 키나제-1을 표적으로 하는 항 혈관 신생 억제제이자 일반적인 간암 유형인 전이성 간세포암 및 다양한 고형 종양 치료를 위한 ALK-1 항체(GT90001)를 개발 중입니다.
자세히 보기 Kintor Pharmaceutical Limited 기본 사항 요약 Kintor Pharmaceutical 의 수익과 매출은 시가총액과 어떻게 비교하나요? 9939 기본 통계 시가총액 HK$419.98m 수익(TTM ) -HK$978.67m 수익(TTM ) n/a
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 9939 손익 계산서(TTM ) 수익 CN¥0 수익 비용 CN¥41.10m 총 이익 -CN¥41.10m 기타 비용 CN¥879.10m 수익 -CN¥920.20m
주당 순이익(EPS) -2.13 총 마진 0.00% 순이익 마진 0.00% 부채/자본 비율 59.8%
9939 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/28 10:27 장 마감 주가 2024/12/27 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Kintor Pharmaceutical Limited 8 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Peng Zou China International Capital Corporation Limited Bing Zhao China Renaissance Securities Blanco Zhou China Renaissance Securities
5 더 많은 분석가 보기 
